Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

T cells are crucial for immune functions to maintain health and prevent disease. T cell
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …

Despite no apparent defects in T cell priming and recruitment to tumors, a large subset of T
cell rich tumors fail to respond to immune checkpoint blockade (ICB). We leveraged a …

CD8+ T cell responses are critical for anti-tumor immunity. While extensively profiled in the
tumor microenvironment, recent studies in mice identified responses in lymph nodes (LNs) …

Improvements in tumor immunotherapies depend on better understanding of the anti-tumor
T cell response. By studying human tumor-draining lymph nodes (TDLNs), we found that …

Immune-checkpoint blockade (ICB) therapies represent a paradigm shift in the treatment of
human cancers; however, it remains incompletely understood how tumor-reactive T cells …

Immune-related adverse events, particularly severe toxicities such as myocarditis, are major
challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy. The …

Targeted immunotherapy has improved patient survival in head and neck squamous cell
carcinoma (HNSCC), but less than 20% of patients produce a durable response to these …

The development of single-cell and spatial transcriptomics methods was instrumental in the
conception of the Human Cell Atlas initiative, which aims to generate an integrated map of …

Recruitment of lymphocytes into tumors is critical for anti-tumor immunity and efficacious
immunotherapy. We show in murine models that tumor-associated high endothelial venules …